Source: Eur Respir Monogr 2010; 49: 130-139



Rating:

Share or cite this content

Citations should be made in the following way:
P.J. Mazzone. Exhaled volatile organic compounds as biomarkers for respiratory diseases. Eur Respir Monogr 2010; 49: 130-139

Member's Comments

No comment yet.

Related content which might interest you: Monitoring of pediatric asthma by symptoms and lung function versus symptoms, lung function and exhaled NO Source: Annual Congress 2004 - Monitoring childhood asthma Year: 2004 Volatile organic compounds of exhaled breath in lung cancer and lung inflammatory diseases Source: Annual Congress 2013 –Epidemiology, screening and diagnosis of lung cancer Year: 2013 Exhaled breath condensate (EBC): what is sampled and how should it be collected? (recommendations and open issues) Source: Annual Congress 2007 - ERS/ATS joint symposium: the report of the ERS/ATS Task Force on Exhaled Breath Condensate Year: 2007 Novel lung function tests in patients with interstitial lung disease (ILD) Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 Canine scent detection in the diagnosis of lung cancer: revisiting a puzzling phenomenon Source: Eur Respir J 2012; 39: 669-676 Year: 2012 Correlation between lung function and exhaled breath condensate biomarkers of inflammation in pulmonary diseases Source: Annual Congress 2009 - Lung function in adults and children Year: 2009 Exhaled air molecular profiling in relation to inflammatory subtype and activity in COPD Source: Eur Respir J 2011; 38: 1301-1309 Year: 2011 Clinically relevant early functional and diagnostic markers of lung disease in children Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-50-2, page=120 Year: 2006 Surfactant protein B polymorphisms, pulmonary function and COPD in 10,231 individuals Source: Eur Respir J 2011; 37: 791-799 Year: 2011 Using exhaled breath profiles in the discrimination between COPD, lung cancer and their co-morbidity Source: International Congress 2015 – Developments in lung cancer diagnosis Year: 2015 The clinical significance of growth factors measurement in exhaled breath condensates (EBC) among patients with interstitial lung diseases Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease Year: 2010 Lung function and sputum neutrophil changes in an experimental model of virus-induced COPD exacerbations Source: Annual Congress 2005 - COPD: role of infection Year: 2005 Exhaled carbon monoxide correlates with airway neutrophilia in patients with chronic allograft dysfunction (BOS) after lung transplantation Source: Annual Congress 2007 - New insights into clinical lung transplantation Year: 2007 Total desmosines in plasma and urine correlate with lung function Source: Eur Respir J 2012; 39: 839-845 Year: 2012 Analysis of semi-volatile organic compounds in exhaled breath condensate of patients with obstructive lung diseases Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities Year: 2010 Exhaled carbon monoxide measurement in patients with interstitial lung diseases (ILD) Source: Annual Congress 2008 - Clinical aspects of interstitial lung disease Year: 2008 Exhaled breath condensate biomarkers in COPD Source: Eur Respir J 2008; 32: 472-486 Year: 2008 Myeloperoxidase in exhaled breath condensate reflects the status of lung parenchyma during the exacerbation of chronic obstructive pulmonary disease Source: Eur Respir J 2005; 26: Suppl. 49, 54s Year: 2005 Volatile organic compounds in exhaled breath of patients with COPD ± lung cancer and their correlation with FEV1-values Source: International Congress 2014 – The assessment of comorbidities Year: 2014 Respiratory work and its components during exercise in interstitial lung disease, COPD and controls Source: International Congress 2015 – Respiratory muscles and airways function: from physiology to clinical implications Year: 2015